Trial
NCT00706914
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Pulmonary Disease, Chronic Obstructive
Intervention
Once-daily aclidinium/formoterol
Why stopped
Actual sample size of 156 was sufficient to estimate the clinical outcomes.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-15